Keytruda 100mg Injection

About

Pembrolizumab, marketed as Keytruda, is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor, specifically targeting the programmed death-1 (PD-1) receptor. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), pembrolizumab effectively releases the brakes on the immune system, allowing T-cells to recognize and attack cancer cells. This mechanism of action has revolutionized the treatment of various advanced cancers, offering durable responses in patients who previously had limited options.

It is approved for a broad spectrum of malignancies, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and many others, often based on PD-L1 expression or microsatellite instability-high (MSI-H) status. Pembrolizumab harnesses the body's own immune defenses to fight cancer, representing a cornerstone of modern immuno-oncology.

Uses

• Treatment of advanced melanoma.
• Management of non-small cell lung cancer (NSCLC).
• Treatment of head and neck squamous cell carcinoma (HNSCC).
• Management of classical Hodgkin lymphoma (cHL).

Directions For Use

This medication is administered intravenously by a healthcare professional. The dosage and frequency will be determined by your doctor based on your condition.

Benefits

• Induces durable responses in various advanced cancers.
• Improves overall survival in many indications.
• Activates the body's immune system to fight cancer.
• Offers a targeted approach with a distinct mechanism of action.
• Approved for a wide range of tumor types.
• Can lead to long-term disease control for some patients.

Side Effects

• Fatigue
• Nausea
• Diarrhea
• Rash
• Pruritus (itching)
• Decreased appetite
• Arthralgia (joint pain)
• Myalgia (muscle pain)
• Cough
• Dyspnea (shortness of breath)
• Hypothyroidism
• Infusion-related reactions

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during cancer treatment.
• Pregnancy - Pembrolizumab is not recommended during pregnancy due to potential harm to the fetus. Women of childbearing potential should use effective contraception.
• Breastfeeding - It is advised to discontinue breastfeeding during treatment with pembrolizumab and for a period after the last dose, due to potential transfer into breast milk.
• Liver - Monitor liver function tests regularly. Immune-mediated hepatitis can occur, requiring dose interruption or corticosteroid treatment.
• Kidney - No specific dose adjustment is typically required for renal impairment, but caution is advised, and renal function should be monitored.
• Lung - Patients should be closely monitored for signs of immune-mediated pneumonitis, which can be severe and requires prompt intervention.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.